Lundbeck handed massive fine
It was a violation of European competition law when Lundbeck made deals with four generics manufacturers concerning its antidepressant citalopram, the European Commission has decided according to a press release from the Danish company, which also reveals Lundbeck’s intentions to appeal the decision.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app